Moxifloxacin Plus Metronidazole Versus Piperacillin/Tazobactam for the Treatment of Patients With Intra-Abdominal Abscesses - Related Studies

Moxifloxacin Plus Metronidazole Versus Piperacillin/Tazobactam for the Treatment of Patients With Intra-Abdominal Abscesses (MEMO)

This study is currently recruiting participants.

Study NCT00629135. Last updated on March 4, 2008. Information provided by Hannover Medical School

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:


1	Conditions listed in this trial
		Abscess, Intra-Abdominal

2	Additional conditions recognized in this trial
		Abdominal Abscess
		Abscess

3	More general conditions related to this trial
		Infection
		Inflammation
		Pathologic Processes
		Suppuration

4	Additional drug interventions recognized in this trial
		Metronidazole
		Moxifloxacin
		Penicillanic Acid
		Piperacillin
		Piperacillin-tazobactam combination product
		Tazobactam

5	More general drug interventions related to this trial
		Anti-Bacterial Agents
		Anti-Infective Agents
		Antiparasitic Agents
		Antiprotozoal Agents
		Enzyme Inhibitors
		Molecular Mechanisms of Pharmacological Action
		Pharmacologic Actions
		Physiological Effects of Drugs
		Radiation-Sensitizing Agents
		Therapeutic Uses

6	Sponsors listed in this trial
		Hannover Medical School
		Bayer AG Leverkusen